| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $167.9M+16.0% | $144.8M+76.0% | $82.2M-34.1% | $124.8M-40.3% | $208.9M-31.5% | $305.0M+83.6% | $166.1M+349.3% | $37.0M |
| Accounts receivable, net | $140.2M+74.9% | $80.1M+65.3% | $48.5M+43.8% | $33.7M+47.1% | $22.9M+85.1% | $12.4M | — | — |
| Inventories, net | $105.1M+11.3% | $94.5M+44.0% | $65.6M+86.4% | $35.2M+2.3% | $34.4M+113.2% | $16.1M | $0 | — |
| Prepaid clinical development costs | $4.0M+590.1% | $586K+203.6% | $193K-81.2% | $1.0M-9.8% | $1.1M+34.8% | $844K-86.1% | $6.1M+15.3% | $5.3M |
| Prepaid inventory costs | $40.9M+194.8% | $13.9M | — | — | — | — | — | — |
| Other prepaid and current assets | $4.5M+8.2% | $4.2M-7.8% | $4.5M-54.3% | $9.9M-11.7% | $11.2M-3.4% | $11.6M+194.8% | $3.9M+194.2% | $1.3M |
| Total current assets | $462.6M+36.9% | $338.0M+68.1% | $201.1M-18.5% | $246.7M-25.0% | $329.0M-4.9% | $345.9M+63.4% | $211.7M+48.4% | $142.6M |
| Property and equipment, net | $338K+33.1% | $254K | $0-100.0% | $164K-75.3% | $664K-48.0% | $1.3M+11.4% | $1.1M+120.2% | $520K |
| Right of use operating lease assets | $2.9M-47.0% | $5.5M+17.9% | $4.7M+351.3% | $1.0M-45.4% | $1.9M-68.5% | $6.0M+293.6% | $1.5M | — |
| Intangible assets | $56K+0.0% | $56K+0.0% | $56K+0.0% | $56K+0.0% | $56K+0.0% | $56K+0.0% | $56K+0.0% | $56K |
| Total assets | $465.9M+35.5% | $343.8M+67.1% | $205.8M-17.0% | $247.9M-35.0% | $381.6M+8.0% | $353.3M+64.7% | $214.4M+49.5% | $143.5M |
| Accounts payable | $65.1M+26.0% | $51.6M+62.8% | $31.7M+37.7% | $23.0M+31.2% | $17.6M-66.2% | $52.0M+80.1% | $28.9M-35.7% | $44.9M |
| Convertible notes, net of issuance costs | $97.3M+0.5% | $96.7M-63.0% | $261.6M+0.7% | $259.9M+0.6% | $258.3M+44.0% | $179.4M | $0 | — |
| Accrued clinical development costs | $4.1M-18.3% | $5.0M+46.3% | $3.4M-36.6% | $5.4M-22.6% | $7.0M-8.5% | $7.7M-56.2% | $17.5M+9.2% | $16.0M |
| Accrued variable consideration | $88.2M+56.0% | $56.5M+64.9% | $34.3M+55.9% | $22.0M | — | — | — | — |
| Other accrued liabilities | $19.2M-1.8% | $19.6M-21.6% | $25.0M+89.3% | $13.2M-56.6% | $30.4M+22.7% | $24.8M+108.8% | $11.9M+249.0% | $3.4M |
| Royalty sale liability | $208.2M-15.4% | $246.0M | $0 | — | — | — | — | — |
| Deferred revenue from collaborations | $34.5M+304.8% | $8.5M-66.5% | $25.4M+624.3% | $3.5M+453.2% | $634K | $0-100.0% | $2.2M | — |
| Operating lease liabilities | $653K-74.6% | $2.6M-14.9% | $3.0M+354.1% | $665K+26.9% | $524K-84.8% | $3.5M+211.5% | $1.1M | — |
| Total current liabilities | $300.8M+22.2% | $246.2M+57.6% | $156.2M+69.2% | $92.3M+25.8% | $73.4M-22.0% | $94.1M+42.4% | $66.1M+2.7% | $64.3M |
| Long-term debt | $152.2M+8.0% | $141.0M | $0 | — | — | — | — | — |
| Other long-term liabilities | $8.7M | $0 | — | — | — | $1.3M | $0 | — |
| Total liabilities | $767.9M+4.8% | $732.5M+10.9% | $660.8M+15.6% | $571.7M-1.2% | $578.5M+28.7% | $449.4M+131.1% | $194.5M+202.3% | $64.3M |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Common stock, $0.001 par value; 480,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 247,210,341 shares issued at December 31, 2025 and 197,846,661 shares issued at December 31, 2024 | $245K+25.0% | $196K+66.1% | $118K+57.3% | $75K+23.0% | $61K+134.6% | $26K-3.7% | $27K+0.0% | $27K |
| Additional paid-in capital | $1.38B+8.6% | $1.27B+10.3% | $1.15B+7.3% | $1.07B+11.1% | $964.4M+20.9% | $797.7M+11.5% | $715.2M+5.6% | $677.5M |
| Treasury stock, at cost; 1,994,198 shares at December 31, 2025 and December 31, 2024 | -$55.0M+0.0% | -$55.0M+0.0% | -$55.0M+0.0% | -$55.0M | — | — | — | — |
| Accumulated other comprehensive loss | $0 | $0 | $0+100.0% | -$2K+93.5% | -$31K | $0-100.0% | $23K+107.2% | -$319K |
| Accumulated deficit | -$1.62B-1.4% | -$1.60B-3.3% | -$1.55B-15.6% | -$1.34B-21.1% | -$1.11B-31.9% | -$838.8M-20.6% | -$695.3M-16.2% | -$598.1M |
| Total stockholders' deficit | -$302.0M+22.3% | -$388.7M+14.6% | -$455.0M-40.5% | -$323.8M-64.4% | -$196.9M-104.9% | -$96.1M-581.9% | $19.9M-74.8% | $79.1M |
| Total liabilities and stockholders' deficit | $465.9M+35.5% | $343.8M+67.1% | $205.8M-17.0% | $247.9M-35.0% | $381.6M+8.0% | $353.3M+64.7% | $214.4M+49.5% | $143.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.